Smooth Muscle Tumor malady

MalaCards: Smooth Muscle Tumor, also known as smooth muscle tumour of uncertain malignant potential, is related to endometrial stromal sarcoma and tongue cancer. An important gene associated with Smooth Muscle Tumor is DES (desmin), and among its related pathways are Signal transduction_PTEN pathway and DNA damage ATM/ATR regulation of G1/S checkpoint. The drugs dexamethasone and prednisone and the compounds vincristine and threonine have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, uterus and endothelial, and related mouse phenotypes are endocrine/exocrine gland and embryogenesis.

Aliases & Descriptions:

smooth muscle tumor 6 8 32 43 smooth muscle tumour of uncertain malignant potential 6 smooth muscle tumor nos (morphologic abnormality) 6

neoplasm of the smooth muscle 6 neoplasms 43

Diseases related to smooth muscle tumor by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1304)

id	Related Disease	Score	Top Affiliating Genes
1	endometrial stromal sarcoma	31.9	KIT, VIM, MME, ESR1, ACTC1, DES
2	tongue cancer	31.6	LGALS1, CDKN1A, MMP2
3	intravenous leiomyomatosis	31.5	IVL, ESR1, ACTC1, DES
4	myoma	31.1	DES, PGR
5	thyroid cancer	30.7	LGALS1, LGALS3, NME1
6	ovarian cancer	30.7	FSCN1, NME1, PGR
7	endometrial stromal tumor	30.3	VIM, MME, DES
8	meningioma	29.6	PCNA, MKI67, ESR1, PGR
9	colonic neoplasm	29.5	BCL2, CDKN1A, CD44, TP53, NME1
10	intraepithelial neoplasm	29.5	PCNA, CDKN2A, MKI67, TP53
11	nasopharynx carcinoma	29.1	PCNA, BCL2, CDKN2A, IVL, TP53, NME1
12	pancreatic mucinous cystadenoma	29.1	KIT, MME, PGR
13	breast cancer	29.0	CDK2, IFI27, AKT1, ESR1, PTGS2, PGR
14	parathyroid carcinoma	28.9	RB1, LGALS3, MKI67, TP53
15	pancreatic cancer	28.9	VEGFA, LGALS3, CDKN1A, CDK2, AKT1
16	sex cord-gonadal stromal tumor	28.8	VIM, S100B, WT1, DES, PGR
17	squamous cell carcinoma	28.7	LGALS1, LGALS3, CD44, MKI67, CCNA2, NME1
18	male breast cancer	28.5	PCNA, ESR1, PGR
19	mesenchymal cell neoplasm	28.1	PCNA, MTOR, CD44, AKT1
20	lynch syndrome	28.0	CDK2, CD44, MKI67, PTGS2
21	follicular dendritic cell tumor	27.9	S100B, FSCN1, CR2, ACTC1
22	giant cell tumor	27.9	VIM, S100B, ACTC1, DES
23	perineurioma	27.9	KIT, VIM, S100B, DES
24	lipoma	27.9	VIM, LHFPL3, S100A1, CDKN2A, HMGA2, ACTC1
25	adenoid cystic carcinoma	27.8	KIT, PCNA, VIM, LGALS3, S100A1, S100B
26	glomus tumor	27.7	VIM, S100A1, S100B, CALD1, ACTC1, DES
27	brain cancer	27.6	RB1, VEGFA, LGALS1, CDKN1A, CD44, AKT1
28	hematologic cancer	27.5	KIT, VEGFA, MTOR, CCNA2, WT1
29	pituitary tumor	27.3	RB1, BMP2, LGALS3, IFI27, ESR1
30	basal cell carcinoma	27.2	BCL2, LGALS1, LGALS3, CD44, IVL, MME
31	mucinous cystadenocarcinoma	27.1	PCNA, VIM, ACTC1
32	malignant peripheral nerve sheath tumor	27.1	KIT, VIM, S100A1, S100B, CDKN2A, ACTC1
33	perivascular epithelioid cell tumor	27.0	KIT, VIM, MTOR, S100A1, S100B, CDKN2A
34	ovarian mucinous neoplasm	27.0	PCNA, RB1, FSCN1, CDKN1A, CDKN2A, MME
35	pleomorphic adenoma	27.0	PCNA, VIM, BMP2, S100A1, S100B, IGF2
36	anaplastic carcinoma	26.9	VIM, LGALS1, LGALS3, NME1
37	thrombosis	26.9	PCNA, VEGFA, LGALS1, CD44, MMP2, ESR1
38	mixed cell type cancer	26.9	VIM, TP53, DES
39	chromophobe renal cell carcinoma	26.9	KIT, PCNA, VIM, S100A1, MME
40	breast malignant phyllodes tumor	26.7	KIT, VIM, MME, MKI67, CCNA2, IGF2
41	t-cell leukemia	26.7	BCL2, LGALS1, LGALS3, CDK2, AKT1, CR2
42	polymorphous low-grade adenocarcinoma	26.6	KIT, PCNA, VIM, LGALS3, S100A1, S100B
43	childhood mediastinal neurogenic tumor	26.6	WT1, DES
44	craniopharyngioma	26.6	PCNA, VIM, LGALS1, LGALS3, S100A1, MKI67
45	adenomatoid tumor	26.6	VIM, MMP2, WT1, DES
46	mastocytosis	26.5	KIT, VIM, BCL2, ACTC1
47	kidney cancer	26.4	VEGFA, MTOR, CD44, WT1
48	bronchogenic carcinoma	26.4	CDKN1A, CDKN2A, TP53, PGR
49	granular cell tumor	26.4	VIM, BCL2, S100A1, S100B, MKI67, DES
50	liver cancer	26.3	RB1, VEGFA, BCL2, CDKN1A, CDKN2A, CCNA2

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 dexamethasone, dexamethasone acetate, dexamethasone acetate pwdr [va product], dexamethasone phosphate, dexamethasone sodium phosphate, dexamethasone sodium phosphate pwdr [va product], linolenic acid, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone, prednisolone acetate, prednisolone acetate pwdr [va product], prednisolone pwdr [va product], prednisolone sodium phosphate, prednisolone tebutate, prednisone, prednisone pwdr [va product]

MalaCards organs/tissues related to smooth muscle tumor:

²²

MGI Mouse Phenotypes related to smooth muscle tumor:

²⁵ (show all 24)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	10.2	OXTR, WT1, HMGA2, CCNB1IP1
2	embryogenesis phenotype	MP:0005380	9.9	PGR, NME1, CCNA2, CDK1, VIM, KIT
3	liver/biliary system phenotype	MP:0005370	9.3	TP53, AKT1, APEX1, VEGFA, KIT
4	limbs/digits/tail phenotype	MP:0005371	8.9	HMGA2, ESR1, IGF2, CD44, BMP2, VEGFA
5	hematopoietic system phenotype	MP:0005397	8.7	NME1, CR2, IGF2, CCL11, CCNA2, CDKN1A
6	immune system phenotype	MP:0005387	8.7	KIT, COL4A5, TP53, APEX1, MME, FSCN1
7	renal/urinary system phenotype	MP:0005367	8.3	WT1, COL4A5, CR2, ESR1, CDKN1A, MTOR
8	no phenotypic analysis	MP:0003012	8.3	OXTR, PTGS2, TP53, ESR1, IGF2, CD44
9	reproductive system phenotype	MP:0005389	8.0	VEGFA, BMP2, NME1, OXTR, WT1, PTGS2
10	nervous system phenotype	MP:0003631	7.9	NME1, HMGA2, AKT1, IGF2, MMP2, CD44
11	integument phenotype	MP:0010771	7.7	MME, HMGA2, TP53, OXTR, NME1, PGR
12	behavior/neurological phenotype	MP:0005386	7.6	CD44, IGF2, AKT1, HMGA2, DES, OXTR
13	normal phenotype	MP:0002873	7.5	CCL11, AKT1, COL4A6, WT1, OXTR, PGR
14	adipose tissue phenotype	MP:0005375	7.4	TP53, HMGA2, ESR1, AKT1, CDKN1A, MTOR
15	mortality/aging	MP:0010768	7.3	AKT1, TP53, CR2, COL4A5, DES, NME1
16	growth/size phenotype	MP:0005378	6.5	AKT1, HMGA2, TP53, WT1, ACTC1, OXTR
17	digestive/alimentary phenotype	MP:0005381	6.0	CD44, IGF2, ESR1, TP53, PTGS2, CDKN2A
18	tumorigenesis	MP:0002006	5.8	APEX1, AKT1, ESR1, TP53, PTGS2, NME1
19	skeleton phenotype	MP:0005390	5.8	MMP2, IGF2, AKT1, ESR1, TP53, PTGS2
20	vision/eye phenotype	MP:0005391	5.7	CD44, MMP2, IGF2, TP53, PTGS2, CDKN2A
21	cardiovascular system phenotype	MP:0005385	5.3	IGF2, AKT1, ESR1, TP53, PTGS2, COL4A5
22	muscle phenotype	MP:0005369	4.4	PGR, CDKN2A, CDK2, CDKN1A, S100A1, MTOR
23	cellular phenotype	MP:0005384	4.0	AKT1, IGF2, CCNA2, APEX1, CD44, ESR1
24	homeostasis/metabolism phenotype	MP:0005376	3.6	IGF2, AKT1, ESR1, HMGA2, TP53, PTGS2

Articles related to smooth muscle tumor:

(show top 50)    (show all 53)

id	Title	Authors	Year	Affiliating Genes
1	The phosphatidylinositol 3' kinase-Akt-mammalian targ et of rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and their clinicopathologic implications. (21464729)	Fadare O.... Liang S.X.	2011	AKT1, MTOR
2	Patterns of bone morphogenetic protein-2 expression i n smooth muscle tumors of the uterine corpus and other uterine tissues. (21285872)	Fadare O.... Liang S.X.	2011	BMP2
3	Expression of Ki-67, P53 and progesterone receptors i n uterine smooth muscle tumors. Diagnostic value. (20437637)	PetroviA8 D.... Martinac I.	2010	TP53, PGR
4	Fascin expression in uterine smooth muscle tumors. (19483633)	KEFELI M.... Kandemir B.	2009	FSCN1
5	A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. (19734847)	Lee C.H.... Gilks C.B.	2009	ESR1, WT1
6	Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression. (17944915)	Huang S.E.... Hsu K.F.	2008	VEGFA
7	Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors. (18949416)	Tai W.C.... Hu T.H.	2008	KIT
8	Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. (18580309)	Chen L.... Yang B.	2008	MKI67
9	The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. (18162776)	Atkins K.A.... Rice L.W.	2008	CDKN2A
10	Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus (18565690)	Farah-Klibi F.... Zermani R.	2008	DES
11	Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. (17368523)	Zhu X.Q.... Shi Y.F.	2007	CCL11
12	Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis. (17550381)	ComunoA9lu N.U.... Molinas N.	2007	PGR, ESR1, PTGS2
13	Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. (16330948)	Esposito N.N.... Jones M.W.	2006	RB1
14	Dedifferentiated mixed stromal-smooth muscle tumor of the uterus. Report of a case. (16715633)	ZA!mecnA-k M.... StanA-k M.	2006	VIM
15	Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. (15377824)	GAPkaslan H.... DurmuA9oA9lu F.	2005	TP53, PGR, MKI67
16	Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. (15051039)	Bodner K.... Mayerhofer K.	2004	BCL2
17	Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. (15051038)	Bodner-Adler B.... Mayerhofer K.	2004	MMP2
18	Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). (15488127)	Mayerhofer K.... Czerwenka K.	2004	MKI67
19	Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. (15066464)	Bodner K.... Mayerhofer K.	2004	PGR, ESR1
20	Uterine smooth muscle tumors in potbellied pigs (Sus scrofa) resemble human fibroids: a potential animal model. (15307213)	Mozzachio K.... Dixon D.	2004	ACTC1
21	Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma. (14576480)	Loddenkemper C.... Stein H.	2003	DES, MME, OXTR
22	Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome. (14998087)	Raspollini M.R.... Taddei G.L.	2003	PGR
23	C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus. (12678420)	Raspollini M.R.... Taddei G.L.	2003	KIT
24	Altered post-translational modification of redox factor 1 protein in human uterine smooth muscle tumors. (12161506)	Orii A.... Fujii S.	2002	APEX1
25	A comparative study of esophageal stromal tumors and smooth muscle tumors. (12419156)	Hou Y.... Zheng A.	2002	KIT, DES
26	HMGIC alterations in smooth muscle tumors of soft tissues and other sites. (12419585)	Hisaoka M.... Hashimoto H.	2002	HMGA2
27	An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. (11914617)	Oliva E.... Clement P.B.	2002	DES, MME
28	Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. (11353058)	Chu P.G.... Chang K.L.	2001	DES, ACTC1
29	CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue. (11745414)	Dobashi Y.... Kameya T.	2001	CDK2, IFI27
30	MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. (11567229)	Mittal K.... Demopoulos R.I.	2001	TP53, PGR, ESR1
31	Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. (11727257)	Poncelet C.... Darai E.	2001	CD44
32	h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. (11257619)	Nucci M.R.... Quade B.J.	2001	DES
33	Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. (11127756)	Li S.Q.... Przygodzki R.M.	2000	KIT
34	Pathology and pathophysiology of uterine smooth-muscle tumors. (11035982)	Robboy S.J.... Anderson M.C.	2000	PGR
35	Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors. (10854234)	Noguchi T.... Kameya T.	2000	CDK2, CCNA2, PCNA
36	Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. (10478672)	Miettinen M.... Sobin L.H.	1999	KIT, DES
37	Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors. (10230352)	Schwarz G.... Kiss R.	1999	LGALS3, LGALS1, LGALS2
38	KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. (9881963)	Ernst S.I.... O'Leary T.J.	1998	KIT
39	Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. (9402327)	Jenson H.B.... Murphy S.B.	1997	CR2
40	Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. (7745016)	Vu T.H.... Hoffman A.R.	1995	IGF2
41	Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. (8587250)	Dahan K.... Gould J.M.	1995	COL4A6, COL4A5
42	Quantitation of Ras p21 oncogene and DNA content of gastrointestinal smooth muscle tumors and prognostic significance (7587676)	Cai J.... Zhang Y.	1995	CDKN1A
43	Proliferating-cell nuclear antigen immunocytochemistr y in the evaluation of gastrointestinal smooth-muscle tumors. (7824513)	Sbaschnig R.J.... O'Leary T.J.	1994	PCNA
44	Epithelioid smooth muscle tumor of the uterus, of un known malignant potential (7659830)	Chuaqui R.... Barrena N.	1994	DES
45	Histological and immunohistochemical study and AgNOR analysis of smooth muscle tumors of the digestive tract (7924863)	Wang X.J.... Yu P.L.	1994	VIM, DES
46	An avaII restriction fragment length polymorphism in the insulin-like growth factor II gene and the occurrence of smooth muscle tumors. (7902208)	Gloudemans T.... Sussenbach J.S.	1993	IGF2
47	Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. (8356449)	Zhou J.... Reeders S.T.	1993	COL4A6, COL4A5
48	Expression and CpG methylation of the insulin-like growth factor II gene in human smooth muscle tumors. (1358435)	Gloudemans T.... Sussenbach J.S.	1992	IGF2
49	An immunohistochemical and ultrastructural survey on smooth muscle tumors of the alimentary tract (1477937)	Wen J.	1992	DES
50	Insulin-like growth factor gene expression in human smooth muscle tumors. (2208134)	Gloudemans T.... Sussenbach J.S.	1990	IGF2

Genes related to smooth muscle tumor according to GeneCards:

(show all 47)

id	Symbol	Description	Score	GeneCards Section Context
1	DES	desmin	11.0	Publications
2	ACTC1	actin, alpha, cardiac muscle 1	11.0	Publications
3	CR2	complement component (3d/Epstein Barr virus) receptor 2	11.0	Publications
4	NME1	NME/NM23 nucleoside diphosphate kinase 1	11.0	Publications
5	IGF2	insulin-like growth factor 2 (somatomedin A)	11.0	Publications
6	IFI27	interferon, alpha-inducible protein 27	11.0	Publications
7	HMGA2	high mobility group AT-hook 2	11.0	Publications
8	PGR	progesterone receptor	11.0	Publications
9	S100A1	S100 calcium binding protein A1	11.0
10	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	11.0	Publications
11	MME	membrane metallo-endopeptidase	11.0	Publications
12	MKI67	antigen identified by monoclonal antibody Ki-67	11.0	Publications
13	LGALS3	lectin, galactoside-binding, soluble, 3	11.0	Publications
14	CDK2	cyclin-dependent kinase 2	11.0	Publications
15	CCL11	chemokine (C-C motif) ligand 11	11.0	Publications
16	CCNA2	cyclin A2	11.0	Publications
17	CALD1	caldesmon 1	11.0
18	PCNA	proliferating cell nuclear antigen	11.0	Publications
19	S100B	S100 calcium binding protein B	11.0
20	VIM	vimentin	11.0	Publications
21	ESR1	estrogen receptor 1	11.0	Publications
22	LGALS2	lectin, galactoside-binding, soluble, 2	11.0	Publications
23	CCNB1IP1	cyclin B1 interacting protein 1, E3 ubiquitin protein ligase	11.0
24	FSCN1	fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)	11.0	Publications
25	OXTR	oxytocin receptor	11.0	Publications
26	LGALS1	lectin, galactoside-binding, soluble, 1	11.0	Publications
27	PCP4	Purkinje cell protein 4	11.0
28	APEX1	APEX nuclease (multifunctional DNA repair enzyme) 1	11.0	Publications
29	COL4A6	collagen, type IV, alpha 6	11.0	Publications
30	DCAF5	DDB1 and CUL4 associated factor 5	11.0
31	COL4A5	collagen, type IV, alpha 5	11.0	Publications
32	IVL	involucrin	11.0
33	BMP2	bone morphogenetic protein 2	11.0	Publications
34	RB1	retinoblastoma 1	11.0	Publications
35	WT1	Wilms tumor 1	11.0	Publications
36	CD44	CD44 molecule (Indian blood group)	11.0	Publications
37	CDK1	cyclin-dependent kinase 1	11.0	Publications
38	MMP2	matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)	11.0	Publications
39	MTOR	mechanistic target of rapamycin (serine/threonine kinase)	11.0	Publications
40	TP53	tumor protein p53	11.0	Publications
41	AKT1	v-akt murine thymoma viral oncogene homolog 1	11.0	Publications
42	VEGFA	vascular endothelial growth factor A	11.0	Publications
43	PTGS2	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	11.0	Publications
44	LHFPL3	lipoma HMGIC fusion partner-like 3	11.0
45	BCL2	B-cell CLL/lymphoma 2	11.0	Publications
46	CDKN2A	cyclin-dependent kinase inhibitor 2A	11.0	Publications
47	CDKN1A	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	11.0	Publications

Pathways related to smooth muscle tumor according to GeneDecks:

(show top 50)    (show all 63)

id	Pathway	Score	Top Affiliating Genes
1	Signal transduction_PTEN pathway41	10.7	PCNA
2	DNA damage ATM/ATR regulation of G1/S checkpoint10	10.6	CDK2, CCNA2
3	Progesterone-mediated oocyte maturation20	10.3	CDK2, CDK1
4	Cell cycle_Cell cycle (generic schema)41	10.1	CCNA2, CDK1, CDK2, RB1
5	Cell cycle Cell cycle (generic schema)10	10.0	CCNA2, CDK1, CDK2, RB1
6	Cell cycle_Transition and termination of DNA replication41	10.0	CCNA2, CDK1, CDK2, PCNA
7	Cell cycle Transition and termination of DNA replacation10	10.0	CCNA2, CDK1, CDK2, PCNA
8	Apoptosis and survival Role of CDK5 in neuronal death and survival10	10.0	BCL2
9	Cell cycle_Regulation of G1/S transition (part 2)41	9.9	AKT1, CCNA2, CDK2, RB1
10	Cell cycle Regulation of G1/S transition (part 2)10	9.9	AKT1, CCNA2, CDK2, RB1
11	Cell adhesion_ECM remodeling41	9.8	COL4A6, COL4A5, IGF2, MMP2, CD44
12	Cell adhesion ECM remodeling10	9.8	COL4A6, COL4A5, IGF2, MMP2, CD44
13	Cell cycle ESR1 regulation of G1/S transition10	9.7	RB1, CDKN1A, CDK2, CCNA2, ESR1
14	Cell cycle_ESR1 regulation of G1/S transition41	9.7	ESR1, CCNA2, CDK2, CDKN1A, RB1
15	Estrogen-mediated S-Phase Entry36	9.7	ESR1, CCNA2, CDK2, CDKN1A, RB1
16	GADD45 Pathway36	9.7	TP53, CCNA2, CDK2, CDKN1A, PCNA
17	DNA damage_ATM/ATR regulation of G1/S checkpoint41	9.6	TP53, CCNA2, CDK2, CDKN1A, PCNA
18	ERK Signaling36	9.6	COL4A6, COL4A5, ESR1, IGF2, BMP2, KIT
19	Signal transduction PTEN pathway10	9.5	AKT1, CDKN1A, MTOR, PCNA
20	Telomerase Components in Cell Signaling36	9.4	TP53, AKT1, BMP2, RB1, KIT
21	Akt Signaling36	9.4	KIT, BMP2, CCL11, AKT1
22	Cell Cycle, Mitotic38	9.3	CCNA2, CDKN2A, CDK2, RB1, PCNA
23	PTEN Pathway36	9.3	COL4A6, COL4A5, TP53, BMP2, KIT
24	Glioblastoma Multiforme36	9.2	TP53, AKT1, IGF2, CDK2, CDKN1A, RB1
25	Signal transduction_AKT signaling41	9.1	TP53, AKT1, CDKN1A, MTOR, PCNA
26	Transcription P53 signaling pathway10	9.0	TP53, APEX1, CDKN2A, CDK2, VEGFA
27	Non-small cell lung cancer20	9.0	RB1, CDKN2A, AKT1
28	p53 Signaling36	9.0	BCL2, CDKN1A, AKT1, TP53
29	Apoptosis and survival_Role of CDK5 in neuronal death and survival41	9.0	TP53, AKT1, CDK1, BCL2
30	Rho Family GTPases36	9.0	DES, COL4A6, COL4A5, IGF2, CCL11, BCL2
31	p53 Mediated Apoptosis36	9.0	TP53, AKT1, IGF2, BCL2, BMP2, KIT
32	Selected targets of p5310	9.0	BCL2, CDKN1A, CDK2, CDK1, TP53
33	G1-S Phase Transition36	8.7	TP53, CCNA2, CDKN2A, CDK2, CDKN1A, RB1
34	Cyclins and Cell Cycle Regulation36	8.7	TP53, CCNA2, CDKN2A, CDK2, CDKN1A, RB1
35	p53 signaling pathway20	8.7	TP53, CDK1, CDKN2A, CDK2, CDKN1A
36	ILK Signaling36	8.7	COL4A6, COL4A5, PTGS2, AKT1, IGF2, BMP2
37	Melanoma20	8.5	RB1, CDKN1A, CDKN2A, AKT1, TP53
38	Chronic myeloid leukemia20	8.5	TP53, AKT1, CDKN2A, CDKN1A, RB1
39	Prostate cancer20	8.4	TP53, AKT1, CDK2, CDKN1A, MTOR, BCL2
40	Small cell lung cancer20	8.4	COL4A6, COL4A5, PTGS2, TP53, AKT1, CDK2
41	Cell cycle20	8.3	TP53, CCNA2, CDK1, CDKN2A, CDK2, CDKN1A
42	Mitochondrial Apoptosis36	8.3	TP53, AKT1, IGF2, CDKN2A, BCL2, BMP2
43	Glioma20	8.3	TP53, AKT1, CDKN2A, CDKN1A, MTOR, RB1
44	Bladder cancer20	8.3	TP53, MMP2, CDKN2A, CDKN1A, VEGFA, RB1
45	Cellular Apoptosis Pathway36	8.3	TP53, AKT1, IGF2, CDKN2A, BCL2, BMP2
46	Cell Cycle / Checkpoint Control3	8.1	TP53, CCNA2, APEX1, CDK1, CDKN2A, CDK2
47	Transcription_P53 signaling pathway41	7.4	TP53, APEX1, MMP2, CDKN2A, CDK2, CDKN1A
48	Pathways in cancer20	7.0	RB1, COL4A6, COL4A5, TP53, AKT1, MMP2
49	Molecular Mechanisms of Cancer36	7.0	COL4A6, COL4A5, TP53, AKT1, IGF2, CCL11
50	Pancreatic Adenocarcinoma36	6.6	PTGS2, TP53, AKT1, IGF2, CCNA2, MMP2

Compounds related to smooth muscle tumor according to GeneDecks:

(show top 50)    (show all 283)

id	Compound	Score	Top Affiliating Genes
1	vincristine32 34 9 9	13.4	KIT
2	threonine32	10.2	BMP2, CCL11, WT1
3	roscovitine32	10.1	IFI27, CCNA2, CDK1, VIM, PCNA
4	h2o232	9.7	MME, LGALS3, DES, APEX1
5	hematoxylin32	8.8	ACTC1, CR2, MKI67, IVL, CDKN2A, S100B
6	cyclosporin a32 42	9.6	CR2, ACTC1, PGR, CCL11, CDK2, BMP2
7	arginine32	8.5	OXTR, DES, WT1, COL4A5, AKT1, IFI27
8	bromodeoxyuridine32	8.4	DES, IFI27, PCNA, RB1, VIM, CCNA2
9	ly29400232	8.4	VEGFA, CDK1, CD44, MMP2, CCNA2, IFI27
10	estrogen32	8.3	S100A1, LGALS3, BMP2, PCNA, ACTC1, WT1
11	adpribose32	8.2	DES, TP53, IFI27, CCNA2, APEX1, CDK1
12	rapamycin32 42	9.2	AKT1, IGF2, CCNA2, CDK1, CDK2, MTOR
13	doxorubicin32 34 9 9	11.0	CD44, CDK1, CDK2, MTOR, VIM, KIT
14	matrigel32	7.9	AKT1, RB1, VIM, CCL11, MMP2, MME
15	gefitinib32 34 9 9	10.8	KIT, VIM, VEGFA, MTOR, PTGS2, ESR1
16	cysteine32	7.8	LGALS1, PCNA, LGALS3, S100A1, S100B, NME1
17	olomoucine32 42 9 9	10.7	CCNA2, CDK1, CDKN2A, CDK2, CDKN1A, BCL2
18	nitric oxide32 9 18 9	10.6	NME1, OXTR, DES, CCNA2, APEX1, MKI67
19	irinotecan32 34 9 9	10.2	CDKN1A, KIT, VEGFA, CDKN2A, CDK1, MKI67
20	celecoxib32 42 34 9 18 9	12.2	BCL2, CDKN1A, PCNA, VEGFA, MMP2, MKI67
21	thymidine32 18	8.1	IVL, CD44, CDK1, CDK2, CDKN1A, S100B
22	docetaxel32 34 9 9	10.1	CCNA2, CDK1, CDKN2A, CDKN1A, MTOR, BCL2
23	calcium32 9 18 9	10.1	APEX1, IFI27, CCL11, MKI67, MME, IVL
24	cytarabine32 34 9 9	10.1	CCNA2, KIT, PCNA, APEX1, MME, CDK1
25	flavopiridol32 9 9	9.0	CDKN1A, VEGFA, RB1, KIT, BCL2, CDK2
26	adriamycin32	7.0	PGR, RB1, VIM, DES, TP53, AKT1
27	steroid32	6.9	CCL11, CCNA2, MKI67, MME, IVL, CD44
28	thymidylate32	6.9	TP53, IFI27, CCNA2, MKI67, CDK1, CDKN2A
29	etoposide32 42 9 9	9.9	RB1, BCL2, LGALS1, LGALS3, S100B, CDKN1A
30	tamoxifen32 34 9 9	9.8	PGR, OXTR, TP53, VIM, PCNA, VEGFA
31	arsenite32 18	7.5	PCNA, VEGFA, BCL2, MTOR, PGR, WT1
32	sb 20358032 42	7.5	CDKN1A, BCL2, BMP2, VEGFA, VIM, RB1
33	resveratrol32 9 18 9	9.4	PGR, PTGS2, TP53, ESR1, IFI27, PCNA
34	oxygen32 18	7.2	CDKN2A, CDK2, CDKN1A, LGALS3, LGALS1, BCL2
35	progesterone32 42 9 18 9	10.2	PGR, BCL2, BMP2, RB1, S100A1, S100B
36	oligonucleotide32	6.2	KIT, PCNA, NME1, RB1, VIM, BMP2
37	retinoic acid32 42 18	8.1	PGR, NME1, WT1, ESR1, AKT1, IFI27
38	testosterone32 9 18 9	9.0	MMP2, MME, CD44, CDK1, CDKN2A, CDK2
39	5fluorouracil32	5.8	MMP2, IVL, CDK1, CDKN2A, CDK2, CDKN1A
40	butyrate32	5.7	WT1, TP53, AKT1, IFI27, IGF2, CCL11
41	paclitaxel32 34 9 9	8.7	TP53, ESR1, AKT1, IFI27, IGF2, CCNA2
42	actinomycin d32	5.6	RB1, KIT, CCL11, MME, CD44, CDKN2A
43	vegf32	5.4	MME, MKI67, CCNA2, IGF2, IFI27, AKT1
44	dexamethasone32 42 34 9 9	9.2	S100B, MTOR, LGALS1, BCL2, BMP2, VEGFA
45	tyrosine32	5.2	RB1, KIT, NME1, OXTR, DES, ACTC1
46	genistein32 9 18 9	8.1	CDKN2A, CDK1, MMP2, CCNA2, CCL11, CDK2
47	cycloheximide32	5.1	KIT, MME, CD44, CDK1, CDKN2A, CDK2
48	cisplatin32 34 9 9	8.1	AKT1, IFI27, IGF2, CCNA2, APEX1, MKI67
49	serine32	3.8	MMP2, BCL2, BMP2, VIM, RB1, KIT
50	paraffin32	3.8	NME1, DES, ACTC1, WT1, CR2, TP53

Cellular components related to smooth muscle tumor according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	senescence-associated heterochromatin focus	GO:035985	9.6	CDKN2A, HMGA2
2	PCNA-p21 complex	GO:070557	9.5	PCNA, CDKN1A
3	nucleoplasm	GO:005654	6.8	AKT1, ESR1, TP53, WT1, PGR, CCNA2
4	cytoplasm	GO:005737	4.5	KIT, MME, MKI67, APEX1, CCNA2, AKT1
5	nucleus	GO:005634	4.1	AKT1, CCNB1IP1, CCNA2, APEX1, MKI67, ESR1

Biological processes related to smooth muscle tumor according to GeneDecks:

(show all 26)

id	Name	GO ID	Score	Top Affiliating Genes
1	mitotic cell cycle G2/M transition DNA damage checkpoint	GO:007095	10.3	CDK1, CCNA2, HMGA2
2	digestive tract development	GO:048565	10.1	OXTR, RB1, KIT
3	base-excision repair	GO:006284	10.0	TP53, HMGA2, APEX1, PCNA
4	regulation of transcription involved in G1/S phase of mitotic cell cycle	GO:000083	9.9	PCNA, RB1, CDK1
5	positive regulation of endothelial cell proliferation	GO:001938	9.6	CCL11, MTOR, BMP2, VEGFA
6	senescence-associated heterochromatin focus assembly	GO:035986	9.5	CDKN2A, HMGA2
7	positive regulation of gene expression	GO:010628	9.4	HMGA2, CD44, CDK1, BMP2, VEGFA, KIT
8	branching involved in ureteric bud morphogenesis	GO:001658	9.4	BMP2, BCL2, CD44, WT1
9	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.4	TP53, IGF2, CD44, MTOR, VEGFA
10	positive regulation of cell cycle arrest	GO:071158	9.4	TP53, HMGA2, CDKN2A
11	positive regulation of protein phosphorylation	GO:001934	9.4	AKT1, IGF2, MTOR, BMP2, VEGFA
12	cell aging	GO:007569	9.2	BCL2, CDK1, TP53
13	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.1	AKT1, CD44, BCL2, VEGFA
14	replicative senescence	GO:090399	9.0	TP53, MME, CDKN2A, CDKN1A
15	cellular response to hypoxia	GO:071456	8.9	PTGS2, TP53, MTOR, VEGFA
16	induction of apoptosis by intracellular signals	GO:008629	8.9	BCL2, CDKN1A, AKT1, TP53
17	mitotic cell cycle	GO:000278	8.5	CCNA2, CDK1, CDKN2A, CDK2, CDKN1A, RB1
18	positive regulation of transcription, DNA-dependent	GO:045893	8.5	WT1, TP53, HMGA2, CCNA2, CDKN2A, CDK2
19	cell cycle checkpoint	GO:000075	8.5	TP53, CDK1, CDKN2A, CDK2, CDKN1A, RB1
20	response to drug	GO:042493	8.4	NME1, OXTR, ACTC1, PTGS2, CDK1, CDKN1A
21	Ras protein signal transduction	GO:007265	8.4	RB1, CDKN1A, CDK2, CDKN2A, CDK1, CCNA2
22	G1/S transition of mitotic cell cycle	GO:000082	8.1	CDK1, CDKN2A, CDK2, CDKN1A, BCL2, RB1
23	negative regulation of cell growth	GO:030308	8.0	WT1, TP53, CDKN2A, CDKN1A, BCL2, RB1
24	negative regulation of apoptotic process	GO:043066	7.9	WT1, TP53, HMGA2, AKT1, CD44, CDKN1A
25	negative regulation of cell proliferation	GO:008285	7.9	NME1, WT1, PTGS2, TP53, CDKN2A, CDKN1A
26	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.5	TP53, HMGA2, ESR1, AKT1, CDKN2A, BMP2

Molecular functions related to smooth muscle tumor according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	histone kinase activity	GO:035173	10.1	CDK2, CDK1
2	cyclin binding	GO:030332	9.3	CDKN1A, CDK2, CDK1
3	identical protein binding	GO:042802	8.4	NME1, TP53, ESR1, AKT1, S100B, S100A1
4	protein homodimerization activity	GO:042803	8.1	CR2, PTGS2, S100B, S100A1, LGALS1, BCL2
5	protein binding	GO:005515	3.3	PGR, MME, MMP2, MKI67, APEX1, CCNA2